Final Program

TUESDAY • MAY 17 241
• understand the role of genetics, epigenetics and the microbiome on lung
function in obstructive lung diseases;
• learn about new findings on potential therapeutic strategies and research
endeavors in obstructive lung diseases.
The factors responsible for the initiation, maintenance, progression, and
exacerbations of obstructive lung diseases are incompletely understood. Airway
remodeling, acute and chronic inflammation and airway hyperresponsiveness are
well known established hallmarks of these syndromes. However, the contributions of
microbial and environmental exposures as well as the influence of genetic and
epigenetic changes to disease risk and treatment are being actively investigated,
elucidated and appreciated. This integrated symposium will present insights into the
impact of these diverse factors to the development and progression of asthma and
COPD, and how this knowledge is being applied to identify novel targets for therapy.
Chairing: B. Camoretti-Mercado, PhD, Tampa, FL
T. Pera, PhD, Philadelphia, PA
J.E. Bourke, PhD, Clayton, Australia
9:00 Obstructive Pulmonary Disease: What Went Wrong and How to
Fix It
M. Kraft, MD, Tucson, AZ
Parker B. Francis Speaker
9:20 Detection of Early Stages of Pulmonary Obstructive Disease:
An Ambitious Goal
S.I. Rennard, MD, Melbourn, United Kingdom
9:40 Genomics of Obstructive Lung Diseases: New and Old Players
P.G. Woodruff, MD, MPH, San Francisco, CA
10:00 Epigenetic Control of Smooth Muscle Phenotype
W. Gerthoffer, PhD, Mobile, AL
10:20 Significance and Interactions of the Lung Microbiome in
Obstructive Lung Diseases
S.V. Lynch, PhD, San Francisco, CA
10:40 Searching New Interventions for Obstructive Lung Diseases:
Promises and Challenges
S.R. White, MD, Chicago, IL
There will be a 5-minute discussion after each talk.
This session and the International Conference are supported by an educational grant from
AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
C12
BASIC • CLINICAL • TRANSLATIONAL
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
BIOMARKERS: GUIDEPOSTS IN
THE ROADMAP TO IMPROVED PERSONALIZED
AND PRECISION MEDICINE
Drug and Device Discovery and Development Committee; Assembly on
Thoracic Oncology
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2005/2007 (West Building, Level 2)
Target Audience
Basic, translational and clinical investigators in academia, industry and
government; individuals involved in drug and device discovery and early/late
development, clinical trials and regulatory approval.
Objectives
At the conclusion of this session, the participant will be able to:
• understand what is meant by biomarkers;
• understand the utility of biomarkers in clinical trials,development of
therapeutic innovations, and in health sciences broadly;
• use practical examples of biomarkers in medicine.
This symposium will discuss the importance of Biomarkers in basic, translational
and clinical studies. The advent of personalized and precision medicine requires
an improved ability to distinguish among patients to better diagnose and treat
disease. Biomarkers provide a means to first diagnose disease then subdivide
patient cohorts into categories based on differences in clinical presentation,
disease progression, histopathology, physiology and genetics/genomics.
Biomarkers may serve as surrogate endpoints in clinical trials and a means to
measure the response to therapeutic interventions. Additionally, biomarkers
play critical roles as evidence of target engagement and biological effects in
early development, and early markers of toxicity or harms and patient risk
stratification. The session will define biomarkers, their clinical utility and provide
a development and regulatory perspective on their use in clinical trials.
Chairing: T.F. Reiss, MD, New Hope, PA
J. Moss, MD, PhD, Bethesda, MD
P. Mazzone, MD, MPH, Cleveland, OH
9:00 How to Identify a Biomarker
J.A. Wagner, MD, PhD, Cambridge, MA
9:24 Cross-Talk Among Medical Subspecialties Facilitates
Biomarker Discovery and Use in Clinical Trial Design
R. Vessey, MA, BM, BCh, Summit, NJ
9:48 Biomarkers: Here, There and Everywhere: Lessons from a
Longitudinal Study of LAM
J. Moss, MD, PhD, Bethesda, MD
10:12 Molecular Testing as a Guide to Lung Cancer Therapeutics
C.A. Powell, MD, New York, NY
10:36 The Regulatory Perspective: Acceptability of Biomarkers as
Surrogate Endpoints in Clinical Trials
R. Meyer, MD, Silver Spring, MD
This session and the International Conference are supported by an educational grant from
AstraZeneca LP.
All CME sessions have been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME)
and are free of the control of commercial interests.
C13
BASIC
SCIENTIFIC SYMPOSIUM
CME Credits Available: 2.0
PROGRESS IN STEM CELL BIOLOGY AND DISEASE
APPLICATIONS
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2016/2018 (West Building, Level 2)
TUESDAY MORNING
ATS 2016 • San Francisco